Clinical and spectroscopic improvement in HIV-associated cognitive impairment

B Stankoff; A Tourbah; S Suarez; E Turell; J L Stievenart; C Payan; A Coutellier; S Herson; L Baril; F Bricaire; V Calvez; E A Cabanis; L Lacomblez; C Lubetzki

doi:10.1212/wnl.56.1.112

Clinical and spectroscopic improvement in HIV-associated cognitive impairment

Neurology. 2001 Jan 9;56(1):112-5. doi: 10.1212/wnl.56.1.112.

Authors

B Stankoff¹, A Tourbah, S Suarez, E Turell, J L Stievenart, C Payan, A Coutellier, S Herson, L Baril, F Bricaire, V Calvez, E A Cabanis, L Lacomblez, C Lubetzki

Affiliation

¹ Fédération de Neurologie I, Hôpital Pitié Salpêtrière, and University Paris VI, France.

PMID: 11148248
DOI: 10.1212/wnl.56.1.112

Abstract

To assess the impact of highly active antiretroviral therapy (HAART) on AIDS-associated cognitive impairment, 22 patients with AIDS with (n = 11) and without (n = 11) cognitive deficit were evaluated clinically and by MRS every 3 months for 9 months. Nineteen patients were on HAART at study entry, 21 after 2 months. Cognitively impaired patients presented with a subcorticofrontal deficit and decreased N-acetyl-aspartate in frontal white matter. These clinical and metabolic abnormalities reversed partially on HAART, whereas they remained within normal limits in cognitively unimpaired patients.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

AIDS Dementia Complex / diagnosis*
AIDS Dementia Complex / drug therapy*
Adult
Antiretroviral Therapy, Highly Active*
Female
Humans
Magnetic Resonance Spectroscopy*
Male
Neuropsychological Tests
Prospective Studies
Treatment Outcome